Watson to acquire portfolio of divested generic pharmaceutical products

Download PDF Copy

Jul 28 2011

Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being divested as a result of the merger between Perrigo Company and Paddock Laboratories. The portfolio consists of six products, including four FDA-approved products and two undisclosed development-stage products. Commercialized products in the portfolio include:

Ciclopirox shampoo 1%
Ammonium Lactate Cream 12%
Ammonium Lactate Lotion 12%
Promethazine HCl Suppositories 12.5 and 25 mg

Perrigo will supply the products to Watson under a Manufacturing and Supply Agreement until manufacturing is transferred to Watson or a third party. Additional details, including financial terms, have not been disclosed.

Source:

Watson Pharmaceuticals, Inc.

Posted in: Business / Finance | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

How IoT, AI, and mobile technologies are transforming manufacturing and R&D

Off-label drug helps one boy with autism speak, parents say. But experts want more data.

Study highlights need to establish clinical practice guidelines for surgical patients receiving MOUDs

New technology improves the efficiency of protein production in E. coli

Menopause symptoms disrupt daily life, but few women get treatment

Mass General Brigham study shows US obesity could jump from 40% to 70%

Innovative approaches target PAR2 receptor to alleviate gut pain

Scientists test whether chaya leaves can lower blood sugar in diabetes

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.